Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing EPCAM or inhibition of the PI3K/Akt/mTOR signaling pathway inhibited the hepatic fibrosis and HSC proliferation yet induced HSC apoptosis.
|
31378124 |
2019 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes three upstream pathways of mTOR: the phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway, the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, and the rat sarcoma (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen-extracellular activated protein kinase kinase (MEK)/ extracellular-signal-regulated kinase (ERK) signaling pathway, specifically explored their role in liver fibrosis, hepatitis B, non-alcoholic fatty liver, liver cancer, hepatic ischemia reperfusion and other liver diseases through the regulation of mTOR-mediated autophagy.
|
31835352 |
2019 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the PI3K/mTOR pathway appears to be a promising target for the treatment of liver fibrosis, PCTS revealed likely side effects in the intestine at higher doses.
|
31494146 |
2019 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The novel findings of this study suggested that SA-A could reduce liver fibrosis and the molecular mechanisms behind it are closely associated with the regulation of PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways.
|
31213776 |
2019 |
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This experiment suggests that CPhG liposomes may inhibit the activation of HSCs by inhibiting FAK and then reducing the expression of phosphorylated Akt/PI3K, thereby providing new insights into the application of CPhGs for liver fibrosis.
|
31505837 |
2019 |
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While different signaling pathways are involved in liver fibrosis progression, mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase-protein kinase B/Akt (PI3K/Akt) are the most crucial.
|
31632567 |
2019 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
PHP14 regulates hepatic stellate cells migration in liver fibrosis via mediating TGF-β1 signaling to PI3Kγ/AKT/Rac1 pathway.
|
29098317 |
2018 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, bioinformatics analysis demonstrated that the differentially expressed mRNAs were predominantly enriched in 'ECM‑receptor interaction', 'PI3K‑Akt signaling pathway' and 'focal adhesion' pathways, all of which are essential for liver fibrosis development.
|
29749545 |
2018 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, further enrichment analysis of 31 target proteins indicated that the HIF-1, PI3K-Akt, FoxO, and chemokine signaling pathways may be the primary pathways regulated by FZHY formula in inhibiting the HSCs viability for the treatment of liver fibrosis.
|
29881350 |
2018 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to investigate the antifibrotic efficacy of NR in thioacetamide (TAA)-induced hepatic fibrosis in rats through evaluating NR effect on the PI3K/Akt pathway.
|
28830755 |
2017 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our research primarily focused on the effects of tanshinol on activation and apoptosis of HSC and further investigated PI3K/AKT/mTOR/p70S6K1 signaling pathways' participation in the pathogenesis of hepatic fibrosis in carbon tetrachloride (CCl4)-induced hepatic fibrosis.
|
28371611 |
2017 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quercetin attenuated liver damage by suppressing the TGF-β1/Smads signaling pathway and activating the PI3K/Akt signaling pathway to inhibit autophagy in BDL- or CCl<sub>4</sub>- induced liver fibrosis.
|
28839277 |
2017 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, PTEN mediates macrophages activation by PI3K/Akt/STAT6 signaling pathway, which provides novel compelling evidences on the potential of PTEN in liver injury and opens new cellular target for the pharmacological therapy of liver fibrosis.
|
28095306 |
2017 |
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Actin and PI3K expression was increased in parallel with the development of hepatic fibrosis.
|
28104102 |
2017 |
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis.
|
24326778 |
2013 |